Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
复制标题
波生坦长期治疗对心力衰竭犬左心室功能障碍和重构进展的影响。
DOI：
10.1016/s0735-1097(99)00528-8
复制
发表时间：
2000
影响因子：
24
通讯作者：
Sabbah,HN
中科院分区：
文献类型：
--
作者：
Mishima,T;Tanimura,M;Suzuki,G;Todor,A;Sharov,VG;Goldstein,S;Sabbah,HN
目的在这项研究中，我们检查了波生坦长期治疗对中度心力衰竭犬左心室功能障碍和重塑进展的影响。背景静脉注射波生坦（一种混合的内皮素-1 A型和B型受体拮抗剂）已被证明可以改善心力衰竭（HF）患者和犬的左心室（LV）功能。方法左心室功能障碍是由多种、多种、多种药物引起的，14只犬连续冠状动脉内微栓塞。当LV射血分数（EF）在30%和40%之间时，停止栓塞。狗被随机分为三个月的治疗波生坦（30 mg/kg，每日两次，n = 7）或根本不治疗在未治疗的狗中，EF从开始治疗前的35 ± 1%下降到治疗三个月结束时的29 ± 1（p = 0.001），LV舒张末期容积（EDV）和收缩末期容积（ESV）增加（EDV：71 ± 3 vs. 84 ± 8 ml，p = 0.08; ESV：46 ± 2 vs. 60 ± 6 ml，p = 0.03）。相比之下，在波生坦治疗犬中，EF从开始治疗前的34 ± 2%增加至治疗3个月结束时的39 ± 1%（p = 0.06），EDV和ESV降低（EDV：75 ± 3 vs. 71 ± 4 ml，p = 0.05; ESV：48 ± 2 vs. 43 ± 3 ml，p = 0.01）。此外，与未经治疗的狗相比，用波生坦治疗的狗表现出显着减少LV心肌细胞肥大和LV体积分数间质fibrosis.CONCLUSIONSIn中度HF的狗，长期治疗波生坦防止LV功能障碍的进展，并减弱LV室重构。研究结果支持使用混合内皮素-1受体拮抗剂作为心力衰竭长期治疗的辅助药物。
OBJECTIVESIn this study, we examined the effects of long-term therapy with bosentan on the progression of LV dysfunction and remodeling in dogs with moderate HF.BACKGROUNDAcute intravenous administration of bosentan, a mixed endothelin-1 type A and type B receptor antagonist, was shown to improve left ventricular (LV) function in patients and dogs with heart failure (HF).METHODSLeft ventricular dysfunction was induced by multiple, sequential intracoronary microembolizations in 14 dogs. Embolizations were discontinued when LV ejection fraction (EF) was between 30% and 40%. Dogs were randomized to three months of therapy with bosentan (30 mg/kg twice daily, n = 7) or no therapy at all (control, n = 7).RESULTSIn untreated dogs, EF decreased from 35 ± 1% before initiating therapy to 29 ± 1% at the end of three months of therapy (p = 0.001), and LV end-diastolic volume (EDV) and end-systolic volume (ESV) increased (EDV: 71 ± 3 vs. 84 ± 8 ml, p = 0.08; ESV: 46 ± 2 vs. 60 ± 6 ml, p = 0.03). By contrast, in dogs treated with bosentan, EF tended to increase from 34 ± 2% before initiating therapy to 39 ± 1% at the end of three months of therapy (p = 0.06), and EDV and ESV decreased (EDV: 75 ± 3 vs. 71 ± 4 ml, p = 0.05; ESV: 48 ± 2 vs. 43 ± 3 ml, p = 0.01). Furthermore, compared with untreated dogs, dogs treated with bosentan showed significantly less LV cardiomyocyte hypertrophy and LV volume fraction of interstitial fibrosis.CONCLUSIONSIn dogs with moderate HF, long-term therapy with bosentan prevents the progression of LV dysfunction and attenuates LV chamber remodeling. The findings support the use of mixed endothelin-1 receptor antagonists as adjuncts to the long-term treatment of HF.
登录
查看更多内容
载脂蛋白 B 与内皮素-1 诱导的人类血管收缩之间的相关性
影响因子：
3
作者：
S. C. Romerio;L. Linder;J. Flammer;W. Haefeli
通讯作者：
W. Haefeli
影响因子：
37.8
作者：
Mulder, P;Richard, V;Thuillez, C
通讯作者：
Thuillez, C
内皮素刺激离体大鼠心脏中磷脂的降解。
DOI：
--
发表时间：
1991
期刊：
Biochemical and Biophysical Research Communications - BBRC
影响因子：
--
作者：
M. Prasad
通讯作者：
M. Prasad
影响因子：
20.1
作者：
Fareh, J;Touyz, RM;Thibault, G
通讯作者：
Thibault, G
内皮素 A 受体通过调节钙和钾电流介导心脏抑制
影响因子：
64.8
作者：
K. Ono;G. Tsujimoto;A. Sakamoto;K. Eto;T. Masaki;Y. Ozaki;M. Satake
通讯作者：
M. Satake